# Xeris Biopharma financial performance and analyst updates

> Live situation record from CLSTR: https://clstr.news/situations/xeris-biopharma-financial-performance-and-analyst-updates
> Updated: 2026-08-10T05:12:47.000Z. Sources: 12. Developments: 2.

Xeris Biopharma reported significant growth in its Recorlev revenue, which rose 81% year-over-year to approximately $56.8 million in the second quarter of 2026. The company also received a U.S. patent notice for Keveyis, extending its intellectual property protection through 2039.

Following this, the company reported quarterly revenue of $92.10 million, exceeding expectations, though its earnings per share (EPS) of ($0.18) missed consensus estimates. In response to these financial results, HC Wainwright lowered its Q3 2026 EPS forecast from $0.02 to $0.01. Other analysts have also adjusted their ratings for the stock, moving from ‘strong-buy’ to ‘buy’ or from ‘sell’ to ‘hold.’

## Timeline

### 2026-08-10: Global corporations report varied financial results amid AI and tech shifts

Major companies including Bloom Energy, JPMorgan Chase, and Apple report diverse financial outcomes driven by AI infrastructure demand, semiconductor trends, and shifting market valuations.

11 sources. https://clstr.news/cluster/xeris-biopharma-faces-lowered-earnings-estimates-from-hc-wainwright

### 2026-08-07: Xeris Biopharma reports revenue surge as Trane Technologies sees institutional shifts

Xeris Biopharma reported an 81% surge in Recorlev revenue and secured a new patent for Keveyis, while institutional investors adjusted their positions in Trane Technologies plc.

2 sources. https://clstr.news/cluster/xeris-biopharma-reports-revenue-surge-as-trane-technologies-sees-institutional-shifts

---
Cite as: Xeris Biopharma financial performance and analyst updates. CLSTR, https://clstr.news/situations/xeris-biopharma-financial-performance-and-analyst-updates